TargetMol®高溶解性3D結構多樣性片段庫

The highly soluble structural diversity fragment compound library is constructed in an efficient and modular manner, so it is very suitable for solving the current situation that a large amount of synthetic investment is required to achieve multi-directional fragment growth. The structurally diverse fragments are designed to contain suitable synthetic reactive groups for future fragment growth. The library of highly soluble 3D structural diversity fragments contains 1083 compounds.

TargetMol®高溶解性3D結構多樣性片段庫Product Description

Traditional drug research and development are mainly based on natural active products or screening new drugs from existing compound data, but this method is highly random, blind, and inefficient. Medicinal chemists subsequently developed high-throughput screening (HTS) methods for drug discovery. Many pharmaceutical companies have also established compound libraries containing millions of small molecules and discovered many drug candidates. However, in drug screening with complex targets, HTS has been repeatedly frustrated. It is difficult to screen high-potential compounds, or the screened compounds have high false positives and poor drug-like properties. In this context, Fragment-based drug design (FBDD) came into being. Organic synthesis can transform miniature hits into effective lead compounds. The deficiencies in the current screening of compound libraries usually result in the need for a large amount of synthetic investment to achieve multi-directional fragment growth, which limits the efficiency of the mini-fragment hit modification process. To meet this challenge, we designed a library of highly soluble 3D structural diversity fragments.

The utility of X-ray-based fragment screening and the ability to achieve rapid analog synthesis:

化合物庫定制

我們的化合物庫可以靈活定制！ 了解更多
 

品牌介紹：
TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化域科學家的研究提供業(yè)的產(chǎn)品和服務。TargetMol品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球大的化合物庫和小分子化合物研究供應商之一。

☆ TargetMol®品牌業(yè)提供各域信號通路小分子抑制劑、拮抗劑、天然產(chǎn)物、藥物篩選化合物。
☆ 產(chǎn)品適應在癌癥、免疫學、心血管系統(tǒng)、呼吸、神經(jīng)科學等多項科學域的研發(fā)使用，超過1180萬種小分子化合物。
☆ 提供20000多個小分子抑制劑、天然產(chǎn)物和200多個化合物庫。
☆ 配備完善的化學合成和生物實驗室，可分別提供高品質小分子抑制劑和藥物篩選技術服務。
☆ 每批產(chǎn)品都有嚴格的NMR和HPLC技術檢測，以保證產(chǎn)品高純度高質量。